

BEST AVAILABLE COPY

Patent Attorney's Docket No. <u>012889-086</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Pat	ent Application of)		
Boden W	ASTFELT et al.)	Group Art Unit: 1647	
Applicat	ion No.: 09/938,497)	Examiner: Robert S. L	andsman
	August 27, 2001 FIBRINOGEN BINDING PROTEIN)))	Confirmation No.: 373	JAN 2 2 2003
	REPLY TO RESTRICT AND AMENDMENT TR			TECH CENTER 1600/2900
	Commissioner for Patents ton, D.C. 20231			
Sir:				
Enc	losed is a reply for the above-identified pa	tent	application.	
[]	A Petition for Extension of Time is also	enc	closed.	
[]	A Terminal Disclaimer and a check for requisite Government fee are also enclose	[]:	\$55.00 (2814) [] \$110.00	(1814) to cover the
[]	Also enclosed is			· ·
[]	Small entity status is hereby claimed.			
[]	Applicant(s) request continued examinat [] \$375.00 (2801) [] \$750.00 (1801) fee of	ion due	under 37 C.F.R. § 1.114 under 37 C.F.R. § 1.17(and enclose the
	[] Applicant(s) previously submitted _ requested.	, (on, for which continu	ed examination is
[]	Applicant(s) request suspension of action exceed three months from the filing of the § 1.103(c). The required fee under 37 (c)	nis I	RCE, in accordance with	, which does not 37 C.F.R.
[]	A Request for Entry and Consideration (146/246) is also enclosed.	of S	ubmission under 37 C.F.	R. § 1.129(a)
[X]	No additional claim fee is required.			

BEST AVAILABLE COPY

Amendment/Reply Transmittal Letter Application No. <u>09/938,497</u> Attorney's Docket No. <u>012889-086</u>

Page 2

[] An additional claim fee is required, and is calculated as shown below:

		AMENDED	CLAIM	S	
	No. OF CLAIMS	HIGHEST NO. OF CLAIMS PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	ADDT'L Fee
Total Claims		MINUS =		× \$18.00 (1202) =	
Independent Claims		MINUS =		× \$84.00 (1201) =	
If Amendment adds mu	ltiple depend	lent claims, add \$28	0.00 (1203)		-
Total Amendment Fee					
If small entity status is o	claimed, sub	tract 50% of Total A	Amendment F	ee	·

[]	A claim fee	in the amount of \$ is	enclosed.
[]	Charge \$	to Deposit Account No.	02-4800.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

<u>ب ب</u>

Christopher L. North, Ph. Registration No. 50,433

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: January 21, 2003



Attorney's Docket No. 012889-086

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
Boden WASTFELT et al.) Group Art Unit: 1647	
Application No.: 09/938,497) Examiner: Robert S. Lands	man
Filed: August 27, 2001) Confirmation No.: 3731	RECEIVED
For: FIBRINOGEN BINDING PROTEIN)	JAN 2 2 2003

TECH CENTER 1600/2900

REPLY TO RESTRICTION REQUIREMENT AND AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In complete reply to the Official Action mailed December 18, 2002 (Paper No. 6) please amend the above-captioned application as follows:

IN THE CLAIMS:

Please cancel Claims 1 and 8 without prejudice or disclaimer of the subject matter disclosed therein.

Please replace Claims 9-11 as follows:

Al

9. (Amended) Pharmaceutical composition for the inhibition of Staphylococci binding to fibrinogen comprising a fibrinogen binding protein of claim 12 in combination with a pharmaceutically acceptable carrier.